Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, et al. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. J Thorac Oncol 2021 Oct 11. pii: S1556-0864(21)03207.
PMID: 34648948